Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection~* HER2-positive breast cancer~* Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2~* LVEF of at least 50 percent (%)~Exclusion Criteria:~* Previous systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease~* Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (\</=) 6 months~* Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting~* Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting~* History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria \[NCI-CTC\], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy~* Central nervous system (CNS) metastases~* Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)~* History of other malignancy within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma~* Inadequate bone marrow, liver or renal function~* Uncontrolled hypertension~* Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pertuzumab + Trastuzumab + Taxane (Type: EXPERIMENTAL): Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.

Based on this trial design, predict the completion outcome and termination type (if applicable).